Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

1kṀ1266

Dec 31

30%

chance

ALL

Since the first FDA approval for weight loss, GLP-1 receptor agonists are in the news as new blockbuster drugs.

As of today, neither Novo Nordisk's Ozempic / Wegovy (Semaglutid), nor Eli Lilly's Mounjaro / Tirzepatid are projected to generate more 2023 sales than Merck's Keytruda (Pembrolizumab, a checkpoint inhibitor used in tumor therapy).

This market will resolve YES if a GLP-1 agonist is the best-selling drug in 2025 (new sales) per reliable company or media reports.

Market context

Technology

Weight loss drugs

Get

1,000

to start trading!

People are also trading

Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025

71% chance

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

86% chance

Will a majority government owned company introduce a new GLP-1 drug before 2040?

15% chance

What fraction of US adults will regularly take GLP-1 drugs in 2030?

Affordable weight loss drugs before 2030?

73% chance

By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?

86% chance

Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?

45% chance

Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss

55% chance

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

10% chance

Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?

Sort by:

Does "bestselling" mean "top dollar value" or, like, doses sold?

Does it count if the drug hits multiple targets and one of the targets is GLP-1R agonism? For example, tirzepatide targets both the GLP-1 and GIP receptors.